BioCryst ( (BCRX) ) has issued an announcement.
In January 2025, BioCryst received a notice from Annora Pharma, challenging the patents of its drug ORLADEYO, with potential implications for its market exclusivity in the U.S. Despite this, BioCryst reported strong financial results for 2024, with significant revenue growth and an optimistic outlook for 2025. The company is expanding its pipeline with new clinical trials and aims to further increase ORLADEYO’s accessibility and market reach, particularly for pediatric patients with HAE.
More about BioCryst
BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of treatments for rare diseases. Its primary product is ORLADEYO, an oral medication for the prevention of hereditary angioedema (HAE) attacks, with a market focus on expanding its use in pediatric patients and securing global market access.
YTD Price Performance: 17.62%
Average Trading Volume: 2,443,778
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.91B
Learn more about BCRX stock on TipRanks’ Stock Analysis page.